Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)

Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto, Takako Doi, Kyuichiro Miyara, Hiroki Odagiri, Kaoru Kitamura, Keisuke Ariyoshi, Tempei Miyaji, Hiroto Ishiki, Kenichi Inoue, Chizuko Tsutsumi, Yoshiaki Sagara, Takuhiro Yamaguchi

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Purpose: Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power® (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and l-carnitine, in controlling CRF in breast cancer patients in Japan. Methods: Breast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events. Results: Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed. Conclusion: IP may control moderate-severe CRF in breast cancer patients. Trial registration: The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.

Original languageEnglish
Pages (from-to)637-646
Number of pages10
JournalSupportive Care in Cancer
Volume24
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Keywords

  • Cancer-related fatigue
  • Chemotherapy-induced fatigue
  • Complementary and alternative medicine
  • Quality of life
  • Supplement

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)'. Together they form a unique fingerprint.

Cite this